02898 盛禾生物－Ｂ
SUNHO BIO-B
SUNHO BIO-B
| Listing Date | 2024/05/24 |
| Listing Price | 13.500 |
Subscription Result
- Subscription Rate10.08x
- Guarantee One Lot Size15 lot
- One Lot Success Rate7.82%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sunho Biologics, Inc. was founded in 2018, it is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases.
--
The Group have three Core Products, IAH0968, IAP0971 and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (“ADCC”) enhanced monoclonal antibody (“mAb”), and it have initiated Phase II clinical trials for biliary tract carcinoma (“BTC”) and colorectal cancer (“CRC”). IAP0971 and IAE0972 are both immunocytokines and it have completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (“NSCLC”) and CRC.
--
As of May 6, 2024, the Group had nine pipeline products, in addition to its Core Products, three of which were in the clinical stage, also focusing on the treatment of cancer.
--
The Group’s core business model involves internally discovering, developing and commercializing immunocytokines and other immunotherapies that regulate immune microenvironment by directly modulating both the innate and adaptive immune systems to address the market needs in the fields of oncology and autoimmune diseases.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 34.15M shares |
| No. of International Offer Shares | 30.74M shares |
| No. of HK Offer Shares | 3.42M shares |
| Offer Price | $13.50 |
| Stock Code | 2898 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CMB International Capital Limited, Zhongtai International Securities Limited, ABCI Securities Company Limited, ICBC International Securities Limited, Citrus Securities Limited, Tiger Brokers (HK) Global Limited, Futu Securities International (Hong Kong) Limited, Victory Securities Company Limited, Grand China Securities Limited |
TIME TABLE
| Application Period | May 16 (Thu) - noon, May 21 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 23 (Thu) |
| Result Announcement Date | On or before May 23 (Thu) |
| Result Announcement Date | On or before May 24 (Fri) |
| Dealings in Shares commence on | May 24, 2024. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $13.50 |
| Capitalization | 2.12B |
| NAV / share ($) | $2.25 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 13.50, the net proceeds raised would be HKD 391.60M, of which |
| 28.2% : Used for ongoing and planned clinical trials of IAH0968 in China |
| 35.8% : Used for ongoing and planned clinical trials of IAP0971 in China |
| 36% : Used to fund ongoing and planned clinical trials of IAE0972 in China |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).